Welcome to our dedicated page for Sol Gel Tech SEC filings (Ticker: SLGL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sol-Gel Technologies Ltd. (NASDAQ: SLGL) files reports with the U.S. Securities and Exchange Commission as a foreign private issuer, primarily through annual reports on Form 20-F and current reports on Form 6-K. These SEC filings document the company’s activities as a dermatology-focused developer of topical drug products such as TWYNEO and EPSOLAY and pipeline candidates including SGT-610 and SGT-210.
On this page, you can review Sol-Gel’s Form 6-K submissions that furnish press releases and, in some cases, unaudited condensed consolidated financial statements for specific periods. These filings cover topics such as quarterly and semi-annual financial results, updates on the Phase 3 clinical trial of SGT-610 for Gorlin syndrome, developments in the Phase 1b study of SGT-210 in Darier disease, licensing and product purchase agreements for EPSOLAY and TWYNEO, and corporate actions like the 10-for-1 reverse share split and the transfer of the company’s listing to the Nasdaq Capital Market.
Sol-Gel’s filings also include proxy materials for annual shareholder meetings, auditor appointments, board and executive approvals and other governance matters. Certain press releases attached as exhibits to Form 6-K are expressly incorporated by reference into the company’s registration statements on Form S-8 and Form F-3, as noted in the filings. For investors analyzing SLGL, the 20-F annual report and accompanying risk factor discussions provide additional context on clinical, regulatory, financial and market risks associated with the company’s dermatology portfolio and rare disease programs.
Stock Titan’s SEC filings page for SLGL presents these documents with real-time updates from EDGAR and AI-powered summaries that highlight key points in lengthy disclosures. This helps readers quickly understand Sol-Gel’s financial position, clinical trial status, licensing arrangements and corporate actions without manually parsing every line of each 6-K or 20-F filing.
Sol-Gel Technologies Ltd. ownership disclosure: Great Point Partners, LLC, Dr. Jeffrey R. Jay and Ms. Lillian Nordahl report beneficial ownership of 274,363 shares of Ordinary Shares, equal to 8.45% of the class. The filing states this percentage is based on 3,245,270 shares outstanding as of March 24, 2026.
The reporting group states shared voting and dispositive power over the 274,363 shares and explains those shares include positions held by funds for which Great Point is investment manager; the reporting persons disclaim beneficial ownership except for pecuniary interests. A Joint Filing Agreement dated March 31, 2026 is attached.
Sol-Gel Technologies Ltd. entered into an underwriting agreement for an underwritten registered direct offering of 459,112 ordinary shares at $72.00 per share, raising gross proceeds of approximately $33.1 million. All shares are being sold by the company under its effective Form F-3 shelf registration statement.
The company plans to use the net proceeds primarily to fund continued development and pre-commercialization activities for its lead investigational candidate SGT-610, as well as research and development, with the remainder for working capital and other general corporate purposes. The offering, described as oversubscribed, is expected to close on or about March 25, 2026, subject to customary closing conditions.
Sol-Gel Technologies Ltd. is offering 459,112 ordinary shares at an offering price of $72.00 per share pursuant to a prospectus supplement. The offering is expected to deliver net proceeds of approximately $30.8 million, which the company intends to use to fund continued development and pre-commercial activities for SGT-610 and for working capital and general corporate purposes.
Based on 2,786,158 ordinary shares outstanding as of December 31, 2025, the company projects 3,245,270 ordinary shares outstanding immediately after this offering. Delivery of the ordinary shares is expected on or about March 25, 2026.
Sol-Gel Technologies Ltd. reported insider buying by entities associated with Opaleye Management Inc., a more than ten percent owner. On March 24, 2026, Opaleye, L.P. purchased 34,665 ordinary shares at 72 per share, bringing its holdings to 485,000 shares. A separately managed account overseen by Opaleye Management bought an additional 5,000 shares at 72 per share, increasing that account’s position to 15,000 shares. Opaleye Management Inc. may be deemed to beneficially own these securities as investment manager and portfolio manager, but explicitly disclaims beneficial ownership except to the extent of its pecuniary interest.
Sol-Gel Technologies Ltd ownership disclosure: Opaleye Management Inc., Opaleye, L.P. and James Silverman report beneficial ownership of 460,335 Ordinary Shares, representing 16.52% of the class. The filing states 2,786,158 Ordinary Shares outstanding as of December 31, 2025.
The statement clarifies the Adviser (Opaleye Management Inc.) advises the Fund (Opaleye, L.P.), Mr. Silverman controls the Adviser, and the reported shares are directly held by the Fund. Signatures show Mr. Silverman signed in multiple capacities.
Sol-Gel Technologies Ltd. filed Post-Effective Amendment No. 4 converting its prior Form F-1 registration into a Form F-3 and incorporating its audited financial results for the fiscal year ended December 31, 2025. The amendment does not register any additional securities.
Offering details: the prospectus covers resale by selling shareholders of up to 656,000 ordinary shares (par value NIS 1.0), comprised of 256,000 Investor Warrant Shares, 200,000 Affiliate Shares and 200,000 Affiliate Warrant Shares. Ordinary shares outstanding were 2,809,879 as of March 18, 2026 and would be 3,265,879 assuming issuance of the referenced warrant shares. The company will not receive proceeds from resale transactions, but may receive up to $26,676,000 assuming full cash exercise of the warrants, which the prospectus states would be used for general corporate purposes.
Sol-Gel Technologies Ltd. files its annual report on Form 20-F, detailing a specialty dermatology business that remains deeply loss-making and high risk. The company reported net losses of $27.2M in 2023, $10.6M in 2024 and $6.1M in 2025, leading to an accumulated deficit of $237M as of December 31, 2025.
The auditors included a going-concern explanatory paragraph, reflecting substantial doubt about Sol-Gel’s ability to continue operating without additional capital. Operations have been funded mainly through equity offerings and loans from the controlling shareholder, and management expects significant further losses as it develops SGT-610 and other candidates.
Sol-Gel has FDA-approved products Twyneo and Epsolay but sold its U.S. rights to Mayne in April 2025 for up to $16M in upfront and milestone payments, and relies on license partners in Canada, China and other territories. All current pipeline products remain in development and face extensive clinical, regulatory, funding and commercialization risks.
Sol-Gel Technologies Ltd. executive Yosef Itzik, the Chief Operating Officer, reported his initial beneficial ownership of stock options on Ordinary Shares. He holds options over 2,031 Ordinary Shares at an exercise price of 100.0000 per share, expiring on March 29, 2032.
He also holds options over 566 Ordinary Shares at an exercise price of 56.0000 per share, expiring on March 9, 2033, and 499 Ordinary Shares at an exercise price of 8.9600 per share, expiring on February 18, 2035. The footnotes describe vesting schedules where 25% of each grant vests on a specified initial date, with the remaining portion vesting in equal quarterly installments, subject to his continued service.
Sol-Gel Technologies Ltd. Chief Financial Officer Eyal Ben-Or filed an initial ownership report showing direct holdings of 1,000 Ordinary Shares and several stock option awards. These include options over 7,500 Ordinary Shares at an exercise price of 69.5000 per share, expiring on January 19, 2036. Footnotes state that some options are fully vested, while others vest 25% on specified dates and then in equal quarterly installments over three years, subject to his continued service.